



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

The General Manager National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051 Code: IOLCP	The General Manager BSE Limited. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001 Code: 524164
---	--

IOLCP/CGC/2018
16 November 2018

Subject: Submission of newspaper cutting of un-audited financial results for the quarter and half year ended on 30 September 2018

Pursuant to the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith copies of the newspaper cutting of financial results for the quarter and half year ended on 30 September 2018 published in Business Standard, Financial Express, Economic Times, Jansatta and Punjabi Jagran on 15 & 16 November 2018.

This is for your information and records please.

Thanking You

Yours faithfully
For IOL Chemicals and Pharmaceuticals Limited

(Krishan Singla)
Vice President and Company Secretary



CORE EXIM LIMITED
 known as Aurum Soft Systems Limited)
 CIN: L32200TN1994PLC026958
 3rd Floor, Room No. 7/48, Anna Salai, Chennai - 600002
 : manager.roc@5core.in, Website: www.fivecoreexim.com

Financial Results for the quarter and half year ended 30.09.2018

(Rs. in Lacs)					
Qtr	Quarter Ended		Half Year Ended		Year Ended
	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
19	263.45	137.97	916.64	137.97	382.97
20	5.24	1.80	29.86	2.02	11.25
21	5.24	1.80	29.86	2.02	11.25
22	3.88	1.80	(89.31)	2.02	148.83
23	0.010	0.09	0.02	0.18	0.05
24	1302	1302	1302	1302	1302
25	0	0	0	0	0
26	0.01	0.00	(0.140)	0.00	0.23
27	0.01	0.00	(0.140)	0.00	0.23

ed format of quarterly financial results filed with the Stock Exchanges
 sting and other Disclosure Requirements) Regulations, 2015. The full
 results is available on the websites of the Stock Exchange,
 ny, www.fivecoreexim.com

comprehensive income or any other relevant financial item(s) due to
 l be disclosed by means of a footnote.

Items adjusted in the statement of profit and loss in accordance with IND
 applicable.

regrouped/ reclassified wherever necessary to correspond with the
 d disclosures.

By order of the Board of Directors
 Sd/-
 Surinder Kaur Kalra
 (Managing Director)
 DIN: 00177037

IOL Chemicals and Pharmaceuticals Limited
 Regd. Office : Trident Complex, Raikot Road, Barnala-148101, Punjab

CIN: L24116PB1986PLC007030 www.iolcp.com
 Ph. +91-1679-244701-07, Fax: +91-1679-244708, E-mail: contact@iolcp.com

EXTRACT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2018

(Rs. in Crore)							
Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2018	30 June 2018	30 September 2017	30 September 2018	30 September 2017	31 March 2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	428.70	365.40	218.71	794.10	453.13	1,007.29
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	58.83	19.67	5.84	78.50	9.01	31.30
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	58.83	19.67	5.84	78.50	9.01	31.30
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	38.40	14.41	4.43	52.81	7.41	27.70
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	38.40	14.41	4.43	52.81	7.41	27.05
6	Equity share capital	56.21	56.21	56.21	56.21	56.21	56.21
7	Other equity (Reserves excluding revaluation reserve)	-	-	-	-	-	159.53
8	Earning per share (of Rs.10/- each) (for continuing and discontinued operations)						
	Basic	6.84	2.56	0.79	9.40	1.32	4.93
	Diluted	6.84	2.56	0.79	9.40	1.32	4.93
	Cash	9.67	4.15	2.14	13.82	3.89	9.75

Notes:

- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results are available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com.
- The company enhanced annual installed capacity of Metformin (Unit IV) from 3,000 MT to 4,000 MT with capex of ₹2.71 crore. The Company has also successfully set up Unit V to manufacture Clopidogrel Bisulphate & Fenofibrate with a capacity of 180 MT per annum with capex of ₹19.26 crore. Both capex funded through internal accruals.
- Excise duty realised is included in revenue from operations of periods upto 30 June 2017 and revenue from operations for the subsequent periods are net of Goods and service tax (GST). Accordingly, the figure of revenue from operations for the six months ended 30 September 2018 is not comparable with the figures of six months ended 30 September 2017.
- Effective 1 April 2018, the company has adopted Ind AS 115 revenue from contracts with customers and its application did not have any material impact on the financial results of the company.
- The previous financial period figures have been regrouped/rearranged wherever considered necessary.

By order of the Board
 For IOL Chemicals and Pharmaceuticals Limited
 Sd/-
 Vijay Garg
 Joint Managing Director
 DIN: 06510248

Place: Ludhiana
 Date: 14 November 2018

FINANCIAL EXPRESS



IOL Chemicals and Pharmaceuticals Limited

Regd. Office : Trident Complex, Raikot Road, Barnala-148101, Punjab

CIN: L24116PB1986PLC007030 www.iolcp.com

Ph. +91-1679-244701-07, Fax: +91-1679-244708, E-mail: contact@iolcp.com

EXTRACT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2018

(Rs. in Crore)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2018	30 June 2018	30 September 2017	30 September 2018	30 September 2017	31 March 2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	428.70	365.40	218.71	794.10	453.13	1,007.29
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	58.83	19.67	5.84	78.50	9.01	31.30
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	58.83	19.67	5.84	78.50	9.01	31.30
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	38.40	14.41	4.43	52.81	7.41	27.70
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	38.40	14.41	4.43	52.81	7.41	27.05
6	Equity share capital	56.21	56.21	56.21	56.21	56.21	56.21
7	Other equity (Reserves excluding revaluation reserve)	-	-	-	-	-	159.53
8	Earning per share (of Rs. 10/- each) (for continuing and discontinued operations)						
	Basic	6.84	2.56	0.79	9.40	1.32	4.93
	Diluted	6.84	2.56	0.79	9.40	1.32	4.93
	Cash	9.67	4.15	2.14	13.82	3.89	9.75

Notes:

- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results are available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com.
- The company enhanced annual installed capacity of Metformin (Unit IV) from 3,000 MT to 4,000 MT with capex of ₹2.71 crore. The Company has also successfully set up Unit V to manufacture Clopidogrel Bisulphate & Fenofibrate with a capacity of 180 MT per annum with capex of ₹19.26 crore. Both capex funded through internal accruals.
- Excise duty realised is included in revenue from operations of periods upto 30 June 2017 and revenue from operations for the subsequent periods are net of Goods and service tax (GST). Accordingly, the figure of revenue from operations for the six months ended 30 September 2018 is not comparable with the figures of six months ended 30 September 2017.
- Effective 1 April 2018, the company has adopted Ind AS 115 revenue from contracts with customers and its application did not have any material impact on the financial results of the company.
- The previous financial period figures have been regrouped/rearranged wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited

Sd/-

Vijay Garg

Joint Managing Director

DIN: 06510248

Place: Ludhiana

Date: 14 November 2018

7	Earnings per Share (of Rs 10/-each) (Not Annualised)
	(i) Basic
	(ii) Diluted

Note:

- The above is an extract of the detailed format of financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results are available on the www.nseindia.com and at http://www.bseindia.com and www.starpapers.com.
- The above financial results have been reviewed by the Board of Directors at their respective meetings held on

Place : New Delhi

Date : 14th November, 2018



BROOKS LABORATORIES LIMITED

Regd. Off.: Village Kishanpura, Nalagarh

CIN No.: L24232HR

Tel.: +91 1795 654001/02/03

E-mail : investors@brookslabs.net

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2018

Sr. No.	Particulars	Quarter ended
		30.09.2018 (Unaudited)
1	Total income from operations (net)	1,410.34
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(378.38)
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(378.38)
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(200.09)
5	Total Comprehensive Income/ (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income/(Loss) (after tax)]	(199.89)
6	Equity Share Capital (Face Value Rs. 10/- per share)	1,618.64
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	11,209.05
8	Earnings per share (of Rs. 10/- each) (not annualised)	
	(a) Basic	(1.24)
	(b) Diluted	(1.24)

Notes: The above is an extract of the detailed format of Quarterly/ Half Yearly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other) Regulations, 2015. The full format of the quarterly/half yearly results is available on the www.brookslabs.net.

Date : November 14, 2018

Place : Mumbai



IOL Chemicals and Pharmaceuticals Limited

Regd. Office : Trident Complex, Raikot Road, Barnala-148101, Punjab

CIN: L24116PB1986PLC007030 www.iolcp.com

Ph. +91-1679-244701-07, Fax: +91-1679-244708, E-mail: contact@iolcp.com

EXTRACT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2018

(Rs. in Crore)

Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30 September 2013	30 June 2018	30 September 2017	30 September 2018	30 September 2017	31 March 2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	428.70	365.40	218.71	794.10	453.13	1,007.29
2	Net Profit /(Loss) for the period (before tax, exceptional and/or extraordinary items)	58.83	19.67	5.84	78.50	9.01	31.30
3	Net Profit /(Loss) for the period before tax (after exceptional and/or extraordinary items)	58.83	19.67	5.84	78.50	9.01	31.30
4	Net Profit /(Loss) for the period after tax (after exceptional and/or extraordinary items)	38.40	14.41	4.43	52.81	7.41	27.70
5	Total Comprehensive income for the period [comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	38.40	14.41	4.43	52.81	7.41	27.05
6	Equity share capital	56.21	56.21	56.21	56.21	56.21	56.21
7	Other equity (Reserves excluding revaluation reserve)	-	-	-	-	-	159.53
8	Earning per share (of Rs.10/- each) (for continuing and discontinued operations)						
	Basic	6.84	2.56	0.79	9.40	1.32	4.93
	Diluted	6.84	2.56	0.79	9.40	1.32	4.93
	Cash	9.67	4.15	2.14	13.82	3.89	9.75

Notes:

- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial results are available on the Stock Exchange websites i.e. www.bseindia.com & www.nseindia.com and Company's website www.iolcp.com.
- The company enhanced annual installed capacity of Metformin (Unit IV) from 3,000 MT to 4,000 MT with capex of ₹2.71 crore. The Company has also successfully set up Unit V to manufacture Clopidogrel Bisulphate & Fenofibrate with a capacity of 180 MT per annum with capex of ₹19.26 crore. Both capex funded through internal accruals.
- Excise duty realised is included in revenue from operations of periods upto 30 June 2017 and revenue from operations for the subsequent periods are net of Goods and service tax (GST). Accordingly, the figure of revenue from operations for the six months ended 30 September 2018 is not comparable with the figures of six months ended 30 September 2017.
- Effective 1 April 2018, the company has adopted Ind AS 115 revenue from contracts with customers and its application did not have any material impact on the financial results of the company.
- The previous financial period figures have been regrouped/rearranged wherever considered necessary.

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited
Sd/-

Vijay Garg
Joint Managing Director
DIN: 06510248

Place: Ludhiana
Date: 14 November 2018

IMITED

1-700 071

LTS
018

(₹ in Lakhs)

Quarter Ended	September'17	Unaudited
	24,946.43	
	3,375.88	
	3,375.88	
	2,160.94	
	2,160.88	
	795.25	
	2.72#	

Results filed with
the Requirements)
Financial Results
changes websites:

Dr. Bihari Agarwal
Managing Director
DIN: 00224857

निवेदन

122003, हरियाणा
 www.rtiies.com
 स्टैपलहाउस अनसेक्युरिटीज

(रु. लाखों में)

क्र. सं.	समाप्त छमाही	समाप्त तिमाही	समाप्त वर्ष
2017	30.9.2018	30.9.2017	31.3.2018
2.98	67.65	17.66	150.41
(12)	(425.71)	(99.26)	(43.60)
(12)	(425.71)	(99.26)	(43.60)
(12)	(425.71)	(99.26)	(43.60)
(12)	(425.71)	(99.26)	(43.60)
2.98	1515.38	1515.38	1515.38
			(1730.51)
(98)	रु. (2.81)	रु. (0.66)	रु. (0.29)
(98)	रु. (2.81)	रु. (0.66)	रु. (0.29)

में निदेशक महान हाथ अनुमोदित किने गये; निचम 33 के अंतर्गत लिखित रूप में "सीमित

30 सितम्बर, 2018 को सम्पन्न तिमाही तथा छमाही के स्टैपलहाउस वित्तीय परिणामों का www.rtiiesecurity.com पर उपलब्ध है। बोर्ड के आदेश पर निर्दिष्ट एचड फाइलस लिमिटेड के लिए

रजत कुमार मोहरा
 अध्यक्ष एवं प्रबंध निदेशक

RTIIES LIMITED

35 Colony, New Delhi - 110025
 74999DL1987PLC026617

ended 30th September 2018
 (in Lakhs, Unless Otherwise Stated)

Half Year Ended	Year Ended	
30.09.2018	30.09.2017	31.03.2018
Audited	Un-Audited	Audited
957.01	937.11	1849.93
56.00	53.31	82.05
56.00	53.31	82.05
43.89	45.83	67.83
466.96	466.96	466.96
		1901.79
0.79	0.83	1.23
0.79	0.83	1.23

with the Stock Exchanges under is 2015. The full format of the www.bseindia.com and on the

GENERAL INDUSTRIES LTD.
 Sd/-
 Pawan Kumar Modi
 Jt. Managing Director
 DIN: 00051679

पूरा, बिना किसी भी शर्त के सफल होना चाहिए।

- The successful bidder shall deposit 25% of the bid amount immediately on the sale being knocked down in his/her/its favour and the balance within 15 days by Banker's Cheque / DD drawn in favour of Citibank N.A. Loan A/c Number 131947.
- In case the successful bidder fails to deposit 25% of the bid amount immediately on sale being knocked down in his/her/its favour and/or the balance amount within 15 days, Please note that, in reference to successful bidder(s), EMD is adjustable against the sale consideration receivable by Citibank N.A. Also, EMD is refundable to the unsuccessful bidder(s), the deposit made by the bidder shall be forfeited without any notice and the sale will be cancelled.
- The charges / fees payable for conveyance such as stamp duty, registration fee, maintenance charges electricity charges etc shall be borne by the successful bidder. The Authorized Officer will not be held responsible for any charge, lien, property tax or any other dues to the Government or local body or any other authority in respect of the property under sale.
- The Authorized Officer has the absolute right to accept or reject the bid or adjourn / postpone/cancel the sale/modify any terms and conditions of the sale without any prior notice or assigning any reason therefore.
- The Sale will only be in favour of successful bidder and not his/her nominee. For inspection of properties and other details, intending buyers may contact Mr. Vishal Kumar, Mr. Kapil Jain (C) 0124 4977825 (M)+91- 9958105724 (M) +91- 9811487755.
- This Notice is also to the Borrower(s) Guarantor(s) in particular and the public in general.

Place: Gurgaon
 Date: 15-Nov-2018

Vishal Kumar (Authorised Officer)
 Citibank N.A.

आइओएल केमिकल्स एंड फार्मास्यूटिकल्स लिमिटेड
 पंजीकृत कार्यालय: ट्रीडेंट कॉम्प्लेक्स, राधेकोट रोड, बरनाला - 148 101 (पंजाब)

CIN: L24116PB1989PLC007030 www.ioicp.com

फोन नं. +91-1679-244701-07, फैक्स: +91-1679-244708, ई-मेल: contact@ioicp.com

दिनांक 30 सितंबर, 2018 को समाप्त तिमाही तथा छमाही के लिए वित्तीय परिणामों का सारांश (करोड़ों में)

क्र. सं.	विवरण	समाप्त तिमाही		समाप्त छमाही		समाप्त वर्ष	
		30 सितंबर 2018	30 जून 2018	30 सितंबर 2017	30 सितंबर 2018		30 सितंबर 2017
		अनसेक्युरिटी	अनसेक्युरिटी	अनसेक्युरिटी	अनसेक्युरिटी		अनसेक्युरिटी
1.	प्रचालनों से कुल आय	428.70	365.40	218.71	794.10	453.13	1,007.39
2.	अवधि के लिए शुद्ध लाभ/(हानि) (सर से पूर्व, विशेष तथा/या असमाधान मदी)	58.83	19.67	5.84	78.50	9.01	31.30
3.	कर से पूर्व अवधि के लिए शुद्ध लाभ/(हानि) (विशेष तथा/या असमाधान मदी के बाद)	58.83	19.67	5.84	78.50	9.01	31.30
4.	कर के बाद अवधि के लिए शुद्ध लाभ/(हानि) (विशेष तथा/या असमाधान मदी के बाद)	38.40	14.41	4.43	52.81	7.41	27.70
5.	अवधि के लिए कुल व्यक्तिगत आय (अवधि के लिए (कर के बाद) लाभ/(हानि) को शामिल करने तथा अन्य व्यक्तिगत आय (कर के बाद))	38.40	14.41	4.43	52.81	7.41	27.05
6.	इक्विटी शेयर पूंजी	56.21	56.21	56.21	56.21	56.21	56.21
7.	अन्य इक्विटी (पुनर्निर्धारित अवधि के अतिरिक्त)						159.53
8.	आय प्रति शेयर (रु. 10/- प्रति का) (जारी और बंद प्रचालनों के लिए)						
	मूल	6.84	2.56	0.79	9.40	1.32	4.93
	तनुकृत	6.84	2.56	0.79	9.40	1.32	4.93
	नकदी	9.67	4.15	2.14	13.82	3.89	9.76

विवरण:

- उपरोक्त विवरण तैयारी (सूचीकरण तथा अन्य प्रकृतिकरण) विनियमनों, 2015 के धिनियम 33 के अंतर्गत शेयर बाजार में लाइव की गई तिमाही वित्तीय परिणामों के विस्तृत आरूप का सा है। तिमाही वित्तीय परिणामों का संपूर्ण विवरण शेयर बाजार की वेबसाइट www.bseindia.com तथा www.nseindia.com और कंपनी की वेबसाइट www.ioicp.com पर उपलब्ध है।
- कंपनी ने 2.71 करोड़ रु. की कैपेक्स के साथ मेंटफॉरमिन (यूनिट IV) की वार्षिक स्थापना क्षमता 3,000 एमटी से 4,000 एमटी बढ़ाया है। कंपनी ने 19.26 करोड़ रु. की कैपेक्स के साथ 180 एमटी प्रति वर्ष की क्षमता सहित क्लोरोडोप्रोल चॉपरसल्ट तथा फेनोफेनडॉल के निर्माण के लिए यूनिट V को भी सफलतापूर्वक स्थापित कर लिया है। दोनों कैपेक्स को आंशिक स्थापना के माध्यम से फंड किया गया।
- समूह उत्पाद शुल्क 30 जून 2017 तक की अवधि के प्रचालनों से राजस्व में शामिल तथा अनुवर्ती अवधि के लिए प्रचालनों से राजस्व अस्तु एवं सेवा कर (जीएसटी) का नेट है। तदनुसार 30 सितंबर 2018 को समाप्त छमाही के लिए प्रचालनों से राजस्व के अंकड़े 30 सितंबर 2017 को समाप्त छमाही के अंकड़ों के साथ तुलनीय नहीं है।
- 01 अप्रैल 2018 से प्रभावी, कंपनी ने टपभोक्तओं के साथ अनुबंध से इंटरएस 115 राजस्व अपना लिया है और इसके आधेदत कंपनी के वित्तीय परिणामों पर प्रभाव डालने वाली कोई सामग्री नहीं रखते हैं।
- पूर्व वित्तीय अवधि के आंकड़ों की जहां जल्दी विचार गया, पुनः परीक्षण/पुनः व्यवस्थित किया गया है।

बोर्ड के आदेशानुसार
 कृते आइओएल केमिकल्स एंड फार्मास्यूटिकल्स लिमिटेड
 हरना/-
 विजय गंग
 संयुक्त प्रबंध निदेशक
 DIN: 06510248

स्थान: सुबिदासा
 तिथि: 14 नवंबर 2018

